Outlook Therapeutics Stockholders Approve Reverse Split, Increase Shares
Outlook Therapeutics, Inc. stockholders approved several key proposals at a special meeting on July 16, 2026. These approvals include an amendment to the company's Restated Certificate of Incorporation to increase the authorized number of common stock shares from 260,000,000 to 600,000,000. Additionally, stockholders approved a reverse stock split of the common stock at a ratio between 1-for-10 and 1-for-50, to be determined by the board of directors. The company also received approval for the potential issuance of shares underlying various warrants related to a recent registered direct offering and concurrent private placement.
Key Highlights
- Stockholders approved increasing authorized common stock from 260,000,000 to 600,000,000 shares.
- Stockholders approved a reverse stock split at a ratio of 1-for-10 to 1-for-50, at board discretion.
- Proposal to increase authorized shares received 24,425,476 votes For and 8,690,115 votes Against.
- Reverse stock split proposal received 44,271,885 votes For and 17,765,393 votes Against.
- Stockholders approved potential issuance of shares underlying private placement warrants for up to 16,129,033 shares.
- Stockholders approved potential issuance of shares underlying placement agent warrants for up to 2,258,064 shares.
- Stockholders approved potential issuance of shares underlying previously issued common warrants for up to 2,142,854 shares.
Price Impact
More from OTLK
Outlook Therapeutics Regains Nasdaq Minimum Bid Price Compliance
Outlook Therapeutics FDA Accepts BLA Resubmission; PDUFA July 29, 2026
Outlook Therapeutics Special Meeting on July 16 to Vote on Warrant Issuance, Share Increase, and Reverse Split